SCHEMBL806553

SCHEMBL806553

CCc1cc(-c2n[nH]c(=N)n2-c2cccc3[nH]ccc23)c(C)cc1O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 11/20 0.40
GAA P10253 3/20 0.34
GOT1 P17174 1/20 0.33
KDM4E B2RXH2 1/20 0.32
LMNA P02545 1/20 0.32
PAX8 Q06710 1/20 0.32
HSP90AB1 P08238 2/20 0.32
DRD1 P21728 1/20 0.32
HPGDS O60760 1/20 0.32
DHFR P00374 1/20 0.32
MAPT P10636 1/20 0.32
DRD2 P14416 1/20 0.32
DRD4 P21917 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9925249 0.94 HSP90AA1 (0.41) HSP90AA1GAAGOT1KDM4ELMNA
SCHEMBL13983476 0.89 HSP90AA1 (0.53) HSP90AA1HSP90AB1
SCHEMBL13983147 0.88 HSP90AA1 (0.43) HSP90AA1GAAKDM4ELMNAHSP90AB1
SCHEMBL13983105 0.85 HSP90AA1 (0.45) HSP90AA1GAAKDM4ELMNAPAX8
SCHEMBL14933295 0.83 BRD4 (0.38) HSP90AA1GAAGOT1HPGDSDHFR
SCHEMBL806551 0.83 HSP90AA1 (0.54) HSP90AA1HSP90AB1
SCHEMBL12180265 0.82 HSP90AA1 (0.44) HSP90AA1GAAKDM4ELMNAHSP90AB1
SCHEMBL12287295 0.79 HSP90AA1 (0.38) HSP90AA1GAAKDM4ELMNAPAX8
SCHEMBL8931037 0.79 HSP90AA1 (0.46) HSP90AA1GAAKDM4ELMNAPAX8
SCHEMBL13983473 0.77 HPGD (0.40) HSP90AA1GAAKDM4ELMNAPAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012037072-A1 HSP90 INHIBITORS FOR TREATING NON-SMALL CELL LUNG CANCERS IN WILD-TYPE EGFR AND/OR KRAS PATIENTS SYNTA PHARMACEUTICALS CORPORATION (US) 2012-03-22 WO disclosed
WO-2011149824-A1 CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR SYNTA PHARMACEUTICALS CORP. (US) 2011-12-01 WO disclosed
WO-2008153730-A2 METHOD FOR TREATING PROLIFERATIVE DISORDERS ASSOCIATED WITH MUTATIONS IN C-MET SYNTA PHARMACEUTICALS CORP. (US) 2008-12-18 WO disclosed